![]() Helen is the Chief Medical Officer at Enliven Therapeutics. in Chemistry from the College of William and Mary. in Chemistry from the University of California, Berkeley and a B.S. He is a co-inventor or co-author on over 230 issued patents and peer-reviewed publications. He has led or been a key scientific contributor to over 30 programs, which has resulted in the discovery of more than 15 clinical candidates, most notably: Koselugo™ (selumetinib), Mektovi ® (binimetinib), Tukysa ® (tucatinib), crenolanib, BIIB091, varlitinib tosilate, filanesib, and motolimod. Joe has experience in multiple therapeutic areas, including antibiotics, immunology, cancer, and neuroscience. ![]() He began his pharmaceutical career as a medicinal chemist at Pfizer Groton. He also worked as an Executive Director at AbbVie, Staff Scientist at Genentech, and Senior Director at Array Biopharma. Prior to co-founding Enliven, Joe served as Vice President of Medicinal Chemistry and DMPK at Biogen, a biotechnology company focused on therapies for neurological diseases. Joe is a co-founder of Enliven Therapeutics and serves as the Chief Scientific Officer and a member of the Board of Directors. in Chemistry, with Honors, from Stanford University.Ĭo-founder, Chief Scientific Officer, and Member of the Board of Directors He has also worked as a medicinal chemist at Genentech, where he designed and synthesized small-molecule drugs for the treatment of cancer and neurodegenerative diseases. Sam has also served as Vice President, Business Development and Applications, at Biodesy, a South San Francisco-based biotech startup developing and commercializing novel protein conformation technology for small-molecule drug discovery.Īdditionally, Sam has worked at Roche Venture Fund, where he triaged and sourced investment opportunities in the life sciences industry. Sam started at Stemcentrx as Senior Director, Strategy and Business Development. Prior to co-founding Enliven, Sam was an Executive Director of Research at AbbVie and the Head of Research at AbbVie Stemcentrx. ![]() Sam is a co-founder of Enliven Therapeutics and serves as the Chief Executive Officer and a member of the Board of Directors. Leaders with a track record of success who have built or led research, development and commercial operations at companies including AbbVie, Array BioPharma, Genentech, Biogen, Pharmacyclics, Five Prime Therapeutics-Amgen, Gilead Sciences, and Blueprint Medicines.Ĭo-founder, Chief Executive Officer, and Member of the Board of Directors.Precision oncology and kinase inhibitor experts who have led or been involved with the discovery, development, or commercialization of over 60 small molecule kinase inhibitor programs, including Imbruvica (ibrutinib), Vitrakvi (larotrectinib), Zydelig (idelalisib), ipatasertib (AKT inhibitor), and PF-07284890/ARRY-461 (CNS-penetrant BRAF inhibitor).World-renowned chemists who have been the primary or co-inventor of over 20 product candidates that have been advanced to clinical trials, including four FDA-approved cancer therapies: Koselugo (selumetinib), Mektovi (binimetinib), Tukysa (tucatinib), and Retevmo (selpercatinib).We have assembled a team with significant expertise in drug discovery and development with particular strength in the discovery of small molecule kinase inhibitors.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |